G Protein-Regulated Signaling Dysfunction in Human Disease

Sutherland E.W. , Rall T.W. The relation of adenosine-3',5'-phosphate and phosphorylase to the actions of catecholamines and other hormones. Pharmacol Rev 1960; 12: 265–99.

Wess J. Molecular basis of receptor/G-protein-coupling selectivity. Pharmacol Ther 1998; 80: 231–64.

Pierce K.L. , Premont R.T. , Lefkowitz R.J. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002; 3: 639–50.

Bockaert J. , Pin J.P. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J 1999; 18: 1723–9.

Hall R.A. , Lefkowitz R.J. Regulation of G protein-coupled receptor signaling by scaffold proteins. Circ Res 2002; 91: 672–80.

Brzostowski J.A. , Kimmel A.R. Signaling at zero G: G-protein-independent functions for 7-TM receptors. Trends Biochem Sci 2001; 26: 291–27.

Heuss C. , Gerber U. G-protein-independent signaling by G-protein-coupled receptors. Trends Neurosci 2000; 23: 469–75.

Wall M.A. , Coleman D.E. , Lee E. The structure of the G protein heterotrimer G_ia1b₁gamma₂. Cell 1995; 83: 1047–58.

Lambright D.G. , Sondek J. , Bohm A. The 2.0 A crystal structure of a heterotrimeric G protein. Nature 1996; 379: 311–9.

Tesmer J.J.G. , Sunahara R.K. , Gilman A.G. , Sprang S.R. Crystal structure of the catalytic domains of adenylyl cyclase in a complex with G_sa.GTPgS. Science 1997; 278: 1907–16.

Slep K.C. , Kercher M.A. , He W. Structural determinants for regulation of phosphodiesterase by a G protein at 2.0 A. Nature 2001; 409: 1071–7.

Hamm H.E. , Gilchrist A. Heterotrimeric G proteins. Curr Opin Cell Biol 1996; 8: 189–96.

Hepler J.R. Emerging roles for RGS proteins in cell signalling. Trends Pharmacol Sci 1999; 20: 376–82.

De Vries L. , Zheng B. , Fischer T. The regulator of G protein signaling family. Annu Rev Pharmacol Toxicol 2000; 40: 235–71.

Ross E.M. , Wilkie T.M. GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu Rev Biochem 2000; 69: 795–827.

Kozasa T. , Jiang X.J. , Hart M.J. p115 RhoGEF, a GTPase activating protein for Ga₁₂ and Ga₁₃. Science 1998; 280: 2109–11.

Fukuhara S. , Murga C. , Zohar M. A novel PDZ domain containing guanine nucleotide exchange factor links het-erotrimeric G proteins to Rho. J Biol Chem 1999; 274: 5868–79.

Marinissen M.J. , Gutkind J.S. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 2001; 22: 368–76.

Cabrera J.L. , De Freitas F. , Satpaev D.K. , Slepak V.Z. Identification of the Gb5-RGS7 protein complex in the retina. Biochem Biophys Res Commun 1998; 249: 898–902.

Snow B.E. , Krumins A.M. , Brothers G.M. A G protein gamma subunit-like domain shared between RGS11 and other RGS proteins specifies binding to G_b5 subunits. Proc Natl Acad Sci U S A 1998; 95: 13307–12.

Farfel Z. , Bourne H.R. , Iiri T. The expanding spectrum of G protein diseases. N Engl J Med 1999; 340: 1012–20.

Weetman A.P. Graves’ disease. N Engl J Med 2000; 343: 1236–48.

Berger E.A. , Murphy P.M. , Farber J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17: 657–700.

Murphy P.M. Viral exploitation and subversion of the immune system through chemokine mimicry. Nat Immunol 2001; 2: 116–22.

Arvanitakis L. , Geras-Raaka E. , Varma A. Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 1997; 385: 347–50.

Yang T.Y. , Chen S.C. , Leach M.W. Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J Exp Med 2000; 191: 445–54.

Lerman B.B. , Dong B. , Stein K.M. Right ventricular outflow tract tachycardia due to a somatic cell mutation in G protein subunitalphai2. J Clin Invest 1998; 101: 2862–8.

Pollak M.R. , Brown E.M. , Chou Y-H.W. Mutations in the human Ca²⁺-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 1993; 75: 1297–303.

Brown E.M. Familial hypocalciuric hypercalcemia and other disorders with resistance to extracellular calcium. Endocrinol Metab Clin North Am 2000; 29: 503–22.

Patten J.L. , Johns D.R. , Valle D. Mutation in the gene encoding the stimulatory G protein of adenylate cyclase in Albright's hereditary osteodystrophy. N Engl J Med 1990; 322: 1412–9.

Weinstein L.S. , Yu S. The role of genomic imprinting of Galpha in the pathogenesis of Albright hereditary osteodystrophy. Trends Endocrinol Metab 1999; 10: 81–5.

Weinstein L.S. , Yu S.H. , Warner D.R. , Liu J. Endocrine manifestations of stimulatory G protein a-subunit mutations and the role of genomic imprinting. Endocr Rev 2001; 22: 675–705.

Shenker A. , Chanson P. , Weinstein L.S. Osteoblastic cells derived from isolated lesions of fibrous dysplasia contain activating somatic mutations of the Gs alpha gene. Hum Mol Genet 1995; 4: 1675–6.

Alman B.A. , Greel D.A. , Wolfe H.J. Activating mutations of Gs protein in monostotic fibrous lesions of bone. J Orthop Res 1996; 14: 311–35.

Bianco P. , Riminucci M. , Majolagbe A. Mutations of the GNAS1 gene, stromal cell dysfunction, and osteomalacic changes in non-McCune-Albright fibrous dysplasia of bone. J Bone Miner Res 2000; 15: 120–8.

Liu G. , Duranteau L. , Carel J.C. Leydig-cell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor. N Engl J Med 1999; 341: 1731–6.

Shenker A. , Laue L. , Kosugi S. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 1993; 365: 652–64.

Berson E.L. Retinitis pigmentosa and allied diseases. In: Albert D.M. , Jakobiec F.A. , Azar D.T. , Gragoudas E.S. editors. Principles and practice of ophthalmology. Philadelphia: WB Saunders; 2000. p. 2262–90.

Dryja T.P. , McGee T.L. , Reichel E. A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. Nature 1990; 343: 364–6.

Olsson J.E. , Gordon J.W. , Pawlyk B.S. Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis pigmentosa. Neuron 1992; 9: 815–30.

Naash M.I. , Hollyfield J.G. , al-Ubaidi M.R. , Baehr W. Simulation of human autosomal dominant retinitis pigmentosa in transgenic mice expressing a mutated murine opsin gene. Proc Natl Acad Sci U S A 1993; 90: 5499–503.

Illing M.E. , Rajan R.S. , Bence N.F. , Kopito R.R. A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin pro-teasome system. J Biol Chem 2002; 277: 34150–60.

Saliba R.S. , Munro P.M. , Luthert P.J. , Cheetham M.E. The cellular fate of mutant rhodopsin: quality control, degradation and aggresome formation. J Cell Sci 2002; 115: 2907–18.

Mouradian M.M. Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 2002; 58: 179–85.

Keen T.J. , Inglehearn C.F. , Lester D.H. Autosomal dominant retinitis pigmentosa: four new mutations in rhodopsin, one of them in the retinal attachment site. Genomics 1991; 11: 199–205.

Robinson P.R. , Cohen G.B. , Zhukovsky E.A. , Oprian D.D. Constitutively active mutants of rhodopsin. Neuron 1992; 9: 719–25.

Li T. , Franson W.K. , Gordon J.W. Constitutive activation of phototransduction by K296E opsin is not a cause of photoreceptor degeneration. Proc Natl Acad Sci U S A 1995; 92: 3551–5.

Sung C.H. , Makino C. , Baylor D. , Nathans J. A rhodopsin gene mutation responsible for autosomal dominant retinitis pigmentosa results in a protein that is defective in localization to the photoreceptor outer segment. J Neurosci 1994; 14: 5818–33.

Li T. , Snyder W.K. , Olsson J.E. , Dryja T.P. Transgenic mice carrying the dominant rhodopsin mutation P347S: evidence for defective vectorial transport of rhodopsin to the outer segments. Proc Natl Acad Sci U S A 1996; 93: 14176–81.

Portera-Cailliau C. , Sung C.H. , Nathans J. , Adler R. Apoptotic photoreceptor cell death in mouse models of retinitis pigmentosa. Proc Natl Acad Sci U S A 1994; 91: 974–98.

Berson E.L. , Rosner B. , Weigel-DiFranco C. Disease progression in patients with dominant retinitis pigmentosa and rhodopsin mutations. Invest Ophthalmol Vis Sci 2002; 43: 3027–36.

Rosenfeld P.J. , Cowley G.S. , McGee T.L. A null mutation in the rhodopsin gene causes rod photoreceptor dysfunction and autosomal recessive retinitis pigmentosa. Nat Genet 1992; 1: 209–13.

Huang S.H. , Pittler S.J. , Huang X. Autosomal recessive retinitis pigmentosa caused by mutations in the alpha sub-unit of rod cGMP phosphodiesterase. Nat Genet 1995; 11: 468–71.

McLaughlin M.E. , Sandberg M.A. , Berson E.L. , Dryja T.P. Recessive mutations in the gene encoding the beta-subunit of rod phosphodiesterase in patients with retinitis pigmentosa. Nat Genet 1993; 4: 130–4.

Weitz C.J. , Went L.N. , Nathans J. Human tritanopia associated with a third amino acid substitution in the blue-sensitive visual pigment. Am J Hum Genet 1992; 51: 444–6.

Bareil C. , Hamel C.P. , Delague V. Segregation of a mutation in CNGB1 encoding the beta-subunit of the rod cGMP-gated channel in a family with autosomal recessive retinitis pigmentosa. Hum Genet 2001; 108: 328–34.

McKusick V.A. Mendelian Inheritance in Man. A catalog of human genes and genetic disorders. Baltimore: Johns Hopkins University Press; 1998.

Dryja T.P. , Berson E.L. , Rao V.R. , Oprian D.D. Heterozygous mis-sense mutation in the rhodopsin gene as a cause of congenital stationary night blindness. Nat Genet 1993; 4: 280–3.

Sieving P.A. , Richards J.E. , Naarendorp F. Dark-light: model for nightblindness from the human rhodopsin Gly-90 → Asp mutation. Proc Natl Acad Sci U S A 1995; 92: 880–4.

Rao V.R. , Cohen G.B. , Oprian D.D. Rhodopsin mutation G90D and a molecular mechanism for congenital night blindness. Nature 1994; 367: 639–42.

Sieving P.A. , Fowler M.L. , Bush R.A. Constitutive “light” adaptation in rods from G90D rhodopsin: a mechanism for human congenital nightblindness without rod cell loss. J Neurosci 2001; 21: 5449–60.

Dryja T.P. , Hahn L.B. , Reboul T. , Arnaud B. Missense mutation in the gene encoding the alpha subunit of rod transducin in the Nougaret form of congenital stationary night blindness. Nat Genet 1996; 13: 358–60.

Bourne H.R. , Sanders D.A. , McCormick F. The GTPase super-family: conserved structure and molecular mechanism. Nature 1991; 349: 117–27.

Krengel U. , Schlichting L. , Scherer A. Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules. Cell 1990; 62: 539–48.

Sandberg M.A. , Pawlyk B.S. , Dan J. Rod and cone function in the Nougaret form of stationary night blindness. Arch Ophthalmol 1998; 116: 867–72.

Muradov K.G. , Artemyev N.O. Loss of the effector function in a transducin-alpha mutant associated with Nougaret night blindness. J Biol Chem 2000; 275: 6969–74.

Gal A. , Orth U. , Baehr W. Heterozygous missense mutation in the rod cGMP phosphodiesterase beta-subunit gene in autosomal dominant stationary night blindness. Nat Genet 1994; 7: 64–8.

Parma J. , Duprez L. , Van Sande J. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993; 365: 649–51.

Duprez L. , Parma I. , Van Sande J. Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat Genet 1994; 7: 396–401.

Ren Q. , Kurose H. , Lefkowitz R.J. , Cotecchia S. Constitutively active mutants of the a₂-adrenergic receptor. J Biol Chem 1993; 268: 16483–7.

Fuhrer D. , Wonerow P. , Willgerodt H. , Paschke R. Identification of a new thyrotropin receptor germline mutation (Leu629Phe) in a family with neonatal onset of autosomal dominant nonautoimmune hyperthyroidism. J Clin Endocrinol Metab 1997; 82: 4234–8.

Kopp P. , Jameson J.L. , Roe T.F. Congenital nonautoimmune hyperthyroidism in a nonidentical twin caused by a sporadic germline mutation in the thyrotropin receptor gene. Thyroid 1997; 7: 765–70.

Khoo D.H. , Parma J. , Rajasoorya C. A germline mutation of the thyrotropin receptor gene associated with thyrotoxicosis and mitral valve prolapse in a Chinese family. J Clin Endocrinol Metab 1999; 84: 1459–62.

Tonacchera M. , Van Sande J. , Cetani F. Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia. J Clin Endocrinol Metab 1996; 81: 547–54.

Biebermann H. , Schoneberg T. , Hess C. The first activating TSH receptor mutation in transmembrane domain 1 identified in a family with nonautoimmune hyperthyroidism. J Clin Endocrinol Metab 2001; 86: 4429–33.

Lee Y.S. , Poh L. , Loke K.Y. An activating mutation of the thyrotropin receptor gene in hereditary non-autoimmune hyperthyroidism. J Pediatr Endocrinol Metab 2002; 15: 211–25.

Alberti L. , Proverbio M.C. , Costagliola S. A novel germline mutation in the TSH receptor gene causes nonautoimmune autosomal dominant hyperthyroidism. Eur J Endocrinol 2001; 145: 249–54.

Schwab K.O. , Gerlich M. , Broecker M. Constitutively active germline mutation of the thyrotropin receptor gene as a cause of congenital hyperthyroidism. J Pediatr 1997; 131: 899–904.

Gruters A. , Schoneberg T. , Biebermann H. Severe congenital hyperthyroidism caused by a germ-line neo mutation in the extracellular portion of the thyrotropin receptor. J Clin Endocrinol Metab 1998; 83: 1431–6.

Tonacchera M. , Agretti P. , Rosellini V. Sporadic nonautoimmune congenital hyperthyroidism due to a strong activating mutation of the thyrotropin receptor gene. Thyroid 2000; 10: 859–63.

Esapa C.T. , Duprez L. , Ludgate M. A novel thyrotropin receptor mutation in an infant with severe thyrotoxicosis. Thyroid 1999; 9: 1005–10.

Melmed S. , Ho K. , Klibanski A. Clinical review 75: recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 1995; 80: 3395–402.

Barkan A.L. New options for diagnosing and treating acromegaly. Cleve Clin J Med 1998; 65: 343, 347–9.

Eugster E.A. , Pescovitz O.H. Gigantism. J Clin Endocrinol Metab 1999; 84: 4379–484.

Vallar L. , Spada A. , Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987; 330: 566–8.

Landis C.A. , Masters S.B. , Spada A. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989; 340: 692–6.

Yang I. , Park S. , Ryu M. Characteristics of gsp-positive growth hormone-secreting pituitary tumors in Korean acromegalic patients. Eur J Endocrinol 1996; 134: 720–76.

Yoshimoto K. , Iwahana H. , Fukuda A. Rare mutations of the Gs alpha subunit gene in human endocrine tumors. Mutation detection by polymerase chain reaction-primer-introduced restriction analysis. Cancer 1993; 72: 1386–193.

Shi Y. , Tang D. , Deng J. , Su C. Detection of gsp oncogene in growth hormone-secreting pituitary adenomas and the study of clinical characteristics of acromegalic patients with gsp-positive pituitary tumors. Chin Med J (Engl) 1998; 111: 891–4.

Kim H.J. , Kim M.S. , Park Y.J. Prevalence of Gs alpha mutations in Korean patients with pituitary adenomas. J Endocrinol 2001; 168: 221–6.

Hosoi E. , Yokogoshi Y. , Hosoi E. Analysis of the Gs alpha gene in growth hormone-secreting pituitary adenomas by the polymerase chain reaction-direct sequencing method using paraffin-embedded tissues. Acta Endocrinol (Copenh) 1993; 129: 301–36.

Landis C.A. , Harsh G. , Lyons J. Clinical characteristics of acromegalic patients whose pituitary tumors contain mutant G_s protein. J Clin Endocrinol Metab 1990; 71: 1416–20.

Lyons J. , Landis C.A. , Harsh G. Two G protein oncogenes in human endocrine tumors. Science 1990; 249: 655–69.

Johnson M.C. , Codner E. , Eggers M. Gps mutations in Chilean patients harboring growth hormone-secreting pituitary tumors. J Pediatr Endocrinol Metab 1999; 12: 381–7.

Sunahara R.K. , Tesmer J.J.G. , Gilman A.G. , Sprang S.R. Crystal structure of the adenylyl cyclase activator G_Sa. Science 1997; 278: 1943–7.

Coleman D.E. , Berghuis A.M. , Lee E. Structures of active conformations of G_ia1 and the mechanism of GTP hydrolysis. Science 1994; 265: 1405–12.

Sondek J. , Lambright D.G. , Noel J.P. GTPase mechanism of G proteins from the 1.7-A crystal structure of transducin alpha-GDP-AIF-4. Nature 1994; 372: 276–9.

Bourne H.R. , Landis C.A. , Masters S.B. Hydrolysis of GTP by the alpha-chain of Gs and other GTP binding proteins. Proteins 1989; 6: 222–30.

Freissmuth M. , Gilman A.G. Mutations of GS alpha designed to alter the reactivity of the protein with bacterial toxins. Substitutions at ARG187 result in loss of GTPase activity. J BiolChem 1989; 264: 21907–14.

Carney J.A. , Hruska L.S. , Beauchamp G.D. , Gordon H. Dominant inheritance of the complex of myxomas, spotty pigmentation, and endocrine overactivity. Mayo Clin Proc 1986; 61: 165–72.

Carney J.A. , Gordon H. , Carpenter P.C. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore) 1985; 64: 270–83.

Stratakis C.A. Clinical genetics of multiple endocrine neoplasias, Carney complex and related syndromes. J Endocrinol Invest 2001; 24: 370–83.

Stratakis C.A. , Kirschner L.S. , Carney J.A. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001; 86: 4041–6.

Carney J.A. Differences between nonfamilial and familial cardiac myxoma. Am J Surg Pathol 1985; 9: 53–5.

Stratakis C.A. , Carney J.A. , Lin J.P. Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2. J Clin Invest 1996; 97: 699–705.

Casey M. , Mah C. , Merliss A.D. Identification of a novel genetic locus for familial cardiac myxomas and Carney complex. Circulation 1998; 98: 2560–6.

Kirschner L.S. , Carney J.A. , Pack S.D. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 2000; 26: 89–92.

Kirschner L.S. , Sandrini F. , Monbo J. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the Carney complex. Hum Mol Genet 2000; 9: 3037–46.

Casey M. , Vaughan C.J. , He J. Mutations in the protein kinase A R1 alpha regulatory subunit cause familial cardiac myxomas and Carney complex. J Clin Invest 2000; 106: R31–8.

Michel J.J. , Scott J.D. Akap mediated signal transduction. Annu Rev Pharmacol Toxicol 2002; 42: 235–57.

Tasken K. , Skalhegg B.S. , Tasken K.A. Structure, function, and regulation of human cAMP-dependent protein kinases. Adv Second Messenger Phosphoprotein Res 1997; 31: 191–204.

Burton K.A. , Johnson B.D. , Hausken Z.E. Type II regulatory subunits are not required for the anchoring-dependent modulation of Ca2+ channel activity by cAMP-dependent protein kinase. Proc Natl Acad Sci U S A 1997; 94: 11067–72.

Amieux P.S. , Cummings D.E. , Motamed K. Compensatory regulation of RI alpha protein levels in protein kinase A mutant mice. J Biol Chem 1997; 272: 3993–8.

Felder R.A. , Sanada H. , Xu J. G protein-coupled receptor kinase 4 gene variants in human essential hypertension. Proc Natl Acad Sci U S A 2002; 99: 3872–7.

Fuchs S. , Nakazawa M. , Maw M. A homozygous 1-base pair deletion in the arrestin gene is a frequent cause of Oguchi disease in Japanese. Nat Genet 1995; 10: 360–2.

Yamamoto S. , Sippel K.C. , Berson E.L. , Dryja T.P. Defects in the rhodopsin kinase gene in the Oguchi form of stationary night blindness. Nat Genet 1997; 15: 175–8.

Cheong H.I. , Park H.W. , Ha I.S. Six novel mutations in the vasopressin V2 receptor gene causing nephrogenic diabetes insipidus. Nephron 1997; 75: 431–47.

Gherman R.B. , Bowen E. , Eggleston M.K. Successful pregnancy outcome in a woman with a gain-of-function mutation of the calcium-sensing receptor. A case report. J Reprod Med 1999; 44: 745–77.

Baldwin J.M. , Schertler G.F. , Unger V.M. An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. J Mol Biol 1997; 272: 144–64.

Palczewski K. , Kumasaka T. , Hori T. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000; 289: 739–45.

Muller G. Towards 3D structures of G protein-coupled receptors: a multidisciplinary approach. Curr Med Chem 2000; 7: 861–88.

Costa T. , Herz A. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci U S A 1989; 86: 7321–5.

Weiner D.M. , Burstein E.S. , Nash N. 5-hydroxytrypta-mine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther 2001; 299: 268–76.

Chen G. , Way J. , Armour S. Use of constitutive G protein-coupled receptor activity for drug discovery. Mol Pharmacol 2000; 57: 125–34.

Pausch M.H. G-protein-coupled receptors in Saccharomyces cerevisiae: high-throughput screening assays for drug discovery. Trends Biotechnol 1997; 15: 487–94.

Broach J.R. , Thorner J. High-throughput screening for drug discovery. Nature 1996; 384: 14–6.

Klein I. Validation of genomics-derived drug targets using yeast. Drug Discov Today 2000; 5: 37–8.

Ijzerman A. , Kourounakis A. , van der Klein P. Allosteric modulation of G protein-coupled receptors. Farmaco 2001; 56: 67–70.

Nemeth E.F. , Fox J. Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endocrinol Metab 1999; 10: 66–71.

Collins M.T. , Skarulis M.C. , Bilezikian J.P. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 1998; 83: 1083–8.

Knoflach F. , Mutel V. , Jolidon S. Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc Natl Acad Sci U S A 2001; 98: 13402–7.

Musser B. , Mudumbi R.V. , Liu J. Adenosine Al receptor-dependent and -independent effects of the allosteric enhancer PD 81, 723. J Pharmacol Exp Ther 1999; 288: 446–54.

Birdsall N.J. , Lazareno S. , Popham A. , Saldanha J. Multiple allosteric sites on muscarinic receptors. Life Sci 2001; 68: 2517–24.

Fawzi A.B. , Macdonald D. , Benbow L.L. SCH-202676: an allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors. Mol Pharmacol 2001; 59: 30–7.

Angers S. , Salahpour A. , Bouvier M. Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annu Rev Pharmacol Toxicol 2002; 42: 409–35.

McLatchie L.M. , Fraser N.J. , Main M.J. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998; 393: 333–9.

Aldecoa A. , Gujer R. , Fischer J.A. , Born W. Mammalian calcitonin receptor-like receptor/receptor activity modifying protein complexes define calcitonin gene-related peptide and adrenomedullin receptors in Drosophila Schneider 2 cells. FEBS Lett 2000; 471: 156–60.

Hilairet S. , Foord S.M. , Marshall F.H. , Bouvier M. Protein-protein interaction and not glycosylation determines the binding selectivity of heterodimers between the calcitonin receptor-like receptor and the receptor activity-modifying proteins. J Biol Chem 2001; 276: 29575–81.

Brakeman P.R. , Lanahan A.A. , O'Brien R. Homer: a protein that selectively binds metabotropic glutamate receptors. Nature 1997; 386: 284–8.

Beneken J. , Tu J.C. , Xiao B. Structure of the Homer EVH1 domain-peptide complex reveals a new twist in polyproline recognition. Neuron 2000; 26: 143–54.

Tadokoro S. , Tachibana T. , Imanaka T. Involvement of unique leucine-zipper motif of PSD-Zip45 (Homer 1c/vesl-1L) in group 1 metabotropic glutamate receptor clustering. Proc Natl Acad Sci U S A 1999; 96: 13801–6.

Ciruela F. , Soloviev M.M. , Chan W.Y. , McIlhinney R.A. Homer-1c/Vesl-1L modulates the cell surface targeting of metabotropic glutamate receptor type 1alpha: evidence for an anchoring function. Mol Cell Neurosci 2000; 15: 36–50.

Becamel C. , Alonso G. , Galeotti N. Synaptic multiprotein complexes associated with 5-HT(2C) receptors: a pro-teomic approach. EMBO J 2002; 21: 2332–42.

Hall R.A. , Premont R.T. , Chow C.W. The beta2-adrenergic receptor interacts with the Na+/H+-exchanger regulatory factor to control Na+/H+ exchange. Nature 1998; 392: 626–30.

Holler C. , Freissmuth M. , Nanoff C. G proteins as drug targets. Cell Mol Life Sci 1999; 55: 257–70.

Zhong H. , Neubig R.R. Regulator of G protein signaling proteins: novel multifunctional drug targets. J Pharmacol Exp Ther 2001; 297: 837–45.

Neubig R.R. Regulators of G protein signaling (RGS proteins): novel central nervous system drug targets. J Pept Res 2002; 60: 312–36.

Ferguson S.S. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 2001; 53: 1–24.

Pierce K.L. , Lefkowitz R.J. Classical and new roles of beta-arrestins in the regulation of G-protein-coupled receptors. Nat Rev Neurosci 2001; 2: 727–33.

Paulssen R.H. , Woodson J. , Liu Z. , Ross E.M. Carboxyl-terminal fragments of phospholipase C-beta1 with intrinsic Gq GTPase-activating protein (GAP) activity. J Biol Chem 1996; 271: 26622–9.

Hurley J.H. , Anderson D.E. , Beach B. Structural genomics and signaling domains. Trends Biochem Sci 2002; 27: 48–53.

Hart M.J. , Jiang X.J. , Kozasa T. Direct stimulation of the guanine nucleotide exchange activity of p115 RhoGEF by Ga₁₃. Science 1998; 280: 2112–4.

de Rooij J. , Zwartkruis F.J. , Verheijen M.H. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998; 396: 474–7.

Ma Y.C. , Huang J.Y. , All S. Src tyrosine kinase is a novel direct effector of G proteins. Cell 2000; 102: 635–46.

Peterson Y.K. , Bernard M.L. , Ma H. Stabilization of the GDP-bound conformation of Gialpha by a peptide derived from the G-protein regulatory motif of AGS3. J Biol Chem 2000; 275: 33193–6.

Natochin M. , Gasimov K.G. , Artemyev N.O. Inhibition of GDP/GTP exchange on G alpha subunits by proteins containing G-protein regulatory motifs. Biochemistry 2001; 40: 5322–8.

Kimple R.J. , Kimple M.E. , Betts L. Structural determinants for GoLoco-induced inhibition of nucleotide release by Galpha subunits. Nature 2002; 416: 878–81.

Kumaramanickavel G. , Maw M. , Denton M.J. Missense rhodopsin mutation in a family with recessive RP. Nat Genet 1994; 8: 10–1.

Dryja T.P. , Finn J.T. , Peng Y.W. Mutations in the gene encoding the alpha subunit of the rod cGMP-gated channel in autosomal recessive retinitis pigmentosa. Proc Natl Acad Sci USA 1995; 92: 10177–81.

Nathans J. , Davenport C.M. , Maumenee I.H. Molecular genetics of human blue cone monochromacy. Science 1989; 245: 831–88.

Nathans J. , Maumenee I.H. , Zrenner E. Genetic heterogeneity among blue-cone monochromats. Am J Hum Genet 1993; 53: 987–1000.

Weitz C.J. , Miyake Y. , Shinzato K. Human tritanopia associated with two amino acid substitutions in the blue-sensitive opsin. Am J Hum Genet 1992; 50: 498–507.

Kohl S. , Baumann B. , Rosenberg T. Mutations in the cone photoreceptor G-protein alpha-subunit gene GNAT2 in patients with achromatopsia. Am J Hum Genet 2002; 71: 422–45.

Kohl S. , Marx T. , Giddings I. Total colourblindness is caused by mutations in the gene encoding the alpha-sub-unit of the cone photoreceptor cGMP-gated cation channel. Nat Genet 1998; 19: 257–9.

Kohl S. , Baumann B. , Broghammer M. Mutations in the CNGB3 gene encoding the beta-subunit of the cone photoreceptor cGMP-gated channel are responsible for achromatopsia (ACHM3) linked to chromosome 8q21. Hum Mol Genet 2000; 9: 2107–16.

Gwinn M.R. , Sharma A. , De Nardin E. Single nucleotide polymorphisms of the N-formyl peptide receptor in localized juvenile periodontitis. J Periodontol 1999; 70: 1194–201.

Seifert R. , Wenzel-Seifert K. Defective Gi protein coupling in two formyl peptide receptor mutants associated with localized juvenile periodontitis. J Biol Chem 2001; 276: 42043–9.

Siffert W. , Rosskopf D. , Siffert G. Association of a human G-protein b3 subunit variant with hypertension. Nat Genet 1998; 18: 45–8.

Rosskopf D. , Manthey I. , Habich C. Identification and characterization of Gbeta3s2, a novel splice variant of the G-protein beta3 subunit. Biochem J 2003; 371: 223–32.

Williamson E.A. , Ince P.G. , Harrison D. G-protein mutations in human pituitary adrenocorticotrophic hormone-secreting adenomas. Eur J Clin Invest 1995; 25: 128–31.

Riminucci M. , Collins M.T. , Lala R. An R201H activating mutation of the GNAS1 (Gsalpha) gene in a corticotroph pituitary adenoma. Mol Pathol 2002; 55: 58–60.

Tordjman K. , Stern N. , Ouaknine G. Activating mutations of the Gs alpha-gene in nonfunctioning pituitary tumors. J Clin Endocrinol Metab 1993; 77: 765–79.

Williamson E.A. , Daniels M. , Foster S. Gs alpha and Gi2 alpha mutations in clinically non-functioning pituitary tumours. Clin Endocrinol (Oxf) 1994; 41: 815–20.

Weinstein L.S. , Shenker A. , Gejman P.V. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991; 325: 1688–95.

Suarez H.G. , du Villard J.A. , Caillou B. gsp mutations in human thyroid tumours. Oncogene 1991; 6: 677–9.

Goretzki P.E. , Lyons J. , Stacy-Phipps S. Mutational activation of RAS and GSP oncogenes in differentiated thyroid cancer and their biological implications. World J Surg 1992; 16: 576–81.

Shen Y. , Mamers P. , Jobling T. Absence of the previously reported G protein oncogene (gip2) in ovarian granulosa cell tumors. J Clin Endocrinol Metab 1996; 81: 4159–61.

Ichikawa Y. , Yoshida S. , Suzuki H. Mutation analysis of gonadotropin receptor and G protein genes in various types of human ovarian tumors. Jpn J Clin Oncol 1996; 26: 298–302.

Gicquel C. , Dib A. , Bertagna X. Oncogenic mutations of alpha-Gi2 protein are not determinant for human adrenocortical tumourigenesis. Eur J Endocrinol 1995; 133: 166–72.

Reincke M. , Karl M. , Travis W. , Chrousos G.P. No evidence for oncogenic mutations in guanine nucleotide-binding proteins of human adrenocortical neoplasms. J Clin Endocrinol Metab 1993; 77: 1419–22.

Boston B.A. , Mandel S. , LaFranchi S. , Bliziotes M. Activating mutation in the stimulatory guanine nucleotide-binding protein in an infant with Cushing's syndrome and nodular adrenal hyperplasia. J Clin Endocrinol Metab 1994; 79: 890–3.

Liu J. , Litman D. , Rosenberg M.J. A GNAS1 imprinting defect in pseudohypoparathyroidism type IB. I Clin Invest 2000; 106: 1167–74.

Tsigos C. , Arai K. , Hung W. , Chrousos G.P. Hereditary isolated glucocorticoid deficiency is associated with abnormalities of the adrenocorticotropin receptor gene. J Clin Invest 1993; 92: 2458–61.

Clark A. , McLoughlin L. , Grossman A. Familial glucocorticoid deficiency associated with point mutation in the adrenocorticotropin receptor. Lancet 1993; 341: 461–2.

Baumann G. , Maheshwari H. The dwarfs of Sindh: severe growth hormone (GH) deficiency caused by a mutation in the GH-releasing hormone receptor gene. Acta Paediatr Suppl 1997; 423: 33–8.

Abramowicz M.J. , Duprez L. , Parma J. Familial congenital hypothyroidism due to inactivating mutation of the thyrotropin receptor causing profound hypoplasia of the thyroid gland. J Clin Invest 1997; 99: 3018–24.

Layman L.C. , Cohen D.P. , Jin M. Mutations in gonad-otropin-releasing hormone receptor gene cause hypogonadotropic hypogonadism. Nat Genet 1998; 18: 14–5.

de Roux N. , Young J. , Misrahi M. A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N Engl J Med 1997; 337: 1597–602.

Kremer H. , Kraaij R. , Toledo S.P. Male pseudohermaphroditism due to a homozygous missense mutation of the luteinizing hormone receptor gene. Nat Genet 1995; 9: 160–4.

Gromoll J. , Simoni M. , Nordhoff V. Functional and clinical consequences of mutations in the FSH receptor. Mol Cell Endocrinol 1996; 125: 177–82.

Iiri T. , Herzmark P. , Nakamoto J.M. Rapid GDP release from G_sa in patients with gain and loss of endocrine function. Nature 1994; 371: 164–8.

Pollak M.R. , Brown E.M. , Estep H.L. Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation. Nat Genet 1994; 8: 303–37.

Svensson P.J. , Von Tell D. , Molander M.L. A heterozygous frameshift mutation in the endothelin-3 (EDN-3) gene in isolated Hirschsprung's disease. Pediatr Res 1999; 45: 714–77.

Puffenberger E.G. , Hosoda K. , Washington S.S. A mis-sense mutation of the endothelin-B receptor gene in multi-genic Hirschsprung's disease. Cell 1994; 79: 1257–66.

Attie T. , Till M. , Pelet A. Mutation of the endothelin-receptor B gene in Waardenburg-Hirschsprung disease. Hum Mol Genet 1995; 4: 2407–9.

Abe Y. , Sakurai T. , Yamada T. Functional analysis of five endothelin-B receptor mutations found in human Hirschsprung disease patients. Biochem Biophys Res Commun 2000; 275: 524–31.

Edery P. , Attie T. , Amiel J. Mutation of the endothelin-3 gene in the Waardenburg-Hirschsprung disease (Shah-Waardenburg syndrome). Nat Genet 1996; 12: 442–4.

Hofstra R.M. , Osinga J. , Tan-Sindhunata G. A homozygous mutation in the endothelin-3 gene associated with a combined Waardenburg type 2 and Hirschsprung phenotype (Shah-Waardenburg syndrome). Nat Genet 1996; 12: 445–7.

Ushikubi F. , Okuma M. , Kanaji K. Hemorrhagic thrombocytopathy with platelet thromboxane A2 receptor abnormality: defective signal transduction with normal binding activity. Thromb Haemost 1987; 57: 158–64.

Hirata T. , Kakizuka A. , Ushikubi F. Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 1994; 94: 1662–7.

van den Ouweland A.M. , Dreesen J.C. , Verdijk M. Mutations in the vasopressin type 2 receptor gene (AVPR2) associated with nephrogenic diabetes insipidus. Nat Genet 1992; 2: 99–102.

Pan Y. , Metzenberg A. , Das S. Mutations in the V2 vasopressin receptor gene are associated with X-linked nephrogenic diabetes insipidus. Nat Genet 1992; 2: 103–16.

Rosenthal W. , Seibold A. , Antaramian A. Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus. Nature 1992; 359: 233–5.

Okamoto S. , Hisaoka M. , Ushijima M. Activating Gs(alpha) mutation in intramuscular myxomas with and without fibrous dysplasia of bone. Virchows Arch 2000; 437: 133–7.

Eddy M.C. , Jan De Beur S.M. , Yandow S.M. Deficiency of the alpha-subunit of the stimulatory G protein and severe extraskeletal ossification. J Bone Miner Res 2000; 15: 2074–83.

Shore E.M. , Ann J. , Jan de Beur S. Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. N Engl J Med 2002; 346: 99–106.

Ahmed S.F. , Barr D.G. , Bonthron D.T. GNAS1 mutations and progressive osseous heteroplasia. N Engl J Med 2002; 346: 1669–71.

Karaplis A.C. , He B. , Nguyen M.T. Inactivating mutation in the human parathyroid hormone receptor type 1 gene in Blomstrand chondrodysplasia. Endocrinology 1998; 139: 5255–8.

Zhang P. , Jobert A.S. , Couvineau A. , Silve C. A homozygous inactivating mutation in the parathyroid hormone/parathyroid hormone-related peptide receptor causing Blomstrand chondrodysplasia. J Clin Endocrinol Metab 1998; 83: 3365–8.

Schipani E. , Kruse K. , Juppner H. A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 1995; 268: 98–100.

Taussig R. , Tang W.J. , Hepler J.R. , Gilman A.G. Distinct patterns of bidirectional regulation of mammalian adenylyl cyclases. J Biol Chem 1994; 269: 6093–100.

Jordan J.D. , Carey K.D. , Stork P.J. , Iyengar R. Modulation of rap activity by direct interaction of Galpha(o) with Rap1 GTPase-activating protein. J Biol Chem 1999; 274: 21507–10.

Chen L.T. , Gilman A.G. , Kozasa T. A candidate target for G protein action in brain. J Biol Chem 1999; 274: 26931–8.

Wilkie T.M. , Scherle P.A. , Strathmann M.P. Characterization of G-protein alpha subunits in the Gq class: expression in murine tissues and in stromal and hematopoietic cell lines. Proc Natl Acad Sci U S A 1991; 88: 10049–53.

Watson A.J. , Aragay A.M. , Slepak V.Z. , Simon M.I. A novel form of the G protein beta subunit Gbeta5 is specifically expressed in the vertebrate retina. J Biol Chem 1996; 271: 28154–60.